MTRC is seeking an experienced Evidence Synthesis Specialist to contribute to our evidence synthesis projects, including systematic reviews and value dossiers, in the evolving field of medical devices.

On September 10, 2025, the French National Authority for Health (HAS) published its evaluation principles for the reimbursement of digital medical devices via the list of medical telemonitoring activities (LATM) and advanced reimbursement for therapeutic and telemonitoring digital medical devices (PECAN). The HAS has also updated evaluation principles for reimbursement of medical devices for individual use via the List of Reimbursable Products and Services (LPPR), Intra-DRG (Intra-GHS) List, and transitional support (PECT).

In the third quarter of 2025, the Agency for Health Technology Assessment and Tariff System (AOTMiT) initiated six Med Tech-related assessments in diagnostic imaging, endocrine, in-vitro diagnostics, nephrology and urology, and robotic surgery fields.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of September 22nd, we plan to work on 25 projects. Review the complete list of planned activities in this post.

On August 19, 2025, NHS England announced that most integrated care boards (ICBs, local commissioners) will coordinate their work by gathering in clusters. Thirteen clusters, each comprising two to three ICBs, will be established by the end of 2025, while thirteen ICBs will continue to operate independently.

On September 5, 2025, the Ministry of Health opened a public consultation on a Draft Ministerial Order to update the Common Package of Benefits of the National Health System. The key planned changes are expected in diagnostic imaging, endocrine, gastrointestinal, in-vitro diagnostics, neurology and neurosurgery, and obstetrics and gynecology fields. Input can be submitted via email until September 26, 2025.

MTRC has released a White Paper titled "Evidence Requirements for Non-IVD Diagnostic Technologies under NICE’s HealthTech Programme". This white paper reviews five assessments of non-IVD diagnostic technologies conducted under the former Diagnostics Assessment Programme (DAP) framework. Despite procedural changes, the case studies offer enduring insights into NICE’s evidence expectations and key factors influencing recommendation outcomes. These findings can help inform evidence generation strategies and support market access planning for similar technologies under the current HealthTech framework.

On September 1, 2025, the Institute for Hospital Remuneration Systems (INeK) announced the start of the application process according to §6 (2) KHEntgG (New Examination and Treatment Methods, NUB) for 2026.

In August 2025, the Dutch Healthcare Institute (ZIN) published the report called “Assessment Framework for Feasibility of Care”. It explains how ZIN determines and assesses the feasibility of interventions when deciding on coverage within the basic health insurance.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Seppänen et al. conducted a scoping review to map interventions that reduce the environmental footprint of healthcare across multiple settings.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Champion et al. mapped the newly developed PICOTS-ComTeC framework for defining digital health interventions against 16 international and national frameworks.

On September 6, 2025, the specifications of the call for projects "Third places for MedTech experimentation" were approved. This initiative is part of the France 2030 investment plan and aims to fund the creation of collaborative testing hubs within healthcare facilities to accelerate the development and market access of innovative medical devices, with a specific focus on surgical robotics and implantable medical devices.